The study harnessed high-resolution structural magnetic resonance imaging (MRI) to meticulously examine the cortical morphometric inverse divergence (MIND) within 308 discrete brain regions. By leveraging multiple morphometric features integrated into comprehensive MIND networks, researchers contrasted data from 80 individuals newly diagnosed with CSD and 40 demographically matched healthy controls. The cohort’s design meticulously excluded confounding effects by focusing strictly on treatment-naïve patients experiencing their initial depressive episode following COVID-19 infection.

Statistical analyses employed generalized linear models factoring in critical covariates such as age, sex, and intracranial volume to isolate genuine neuroanatomical differences attributable to CSD. Strikingly, significant elevation of MIND values emerged prominently within the cingulate and supramarginal cortical regions—areas intrinsically linked to emotional regulation, memory consolidation, and language processing. These morphometric deviations bore a strong association with clinical measures of stress and cognitive impairment, independent of the frequency of SARS-CoV-2 infection episodes.

To unravel the molecular substrates underpinning these structural anomalies, the researchers implemented partial least squares (PLS) regression techniques to correlate regional MIND alterations with cortical gene expression profiles sourced from comprehensive spatial transcriptomic atlases. This innovative multi-pronged approach enabled them to identify gene sets whose expression patterns significantly tracked with morphometric disparities. Notably, one latent factor, referred to as PLS4, accounted for 17.7% of variance in MIND measures, with this factor’s positively weighted genes enriched in neurodevelopmental and metabolic pathways, whereas negatively weighted genes predominantly related to immune functions.

Delving deeper, the immune-associated genes (PLS4-) demonstrated preferential expression in microglia and astrocytes—key glial cell types instrumental in neuroinflammation and homeostatic maintenance. These genes localized to cortical layer I, which is implicated in complex cortical-cortical communications. Conversely, the neurodevelopmental and metabolic gene cohort (PLS4+) was markedly enriched in layer V, a principal output layer containing projection neurons critical for corticospinal and subcortical interactions. Such laminar specificity hints at nuanced pathophysiological mechanisms targeting discrete cortical strata.

Temporal developmental enrichment analyses revealed that these transcriptional signatures map onto disruptions occurring during both early brain maturation phases—including fetal and infant stages—and later adult neurodevelopmental periods. This bi-phasic developmental impact suggests a lasting vulnerability that spans across the lifespan, potentially underpinning CSD’s unique clinical phenotype. It also raises provocative questions regarding how SARS-CoV-2 infection may resonate with preexisting neurodevelopmental susceptibilities.

Crucially, this research challenges the simplistic notion that post-COVID depression is merely reactive or psycho-social in origin; rather, it advances a sophisticated multiscale framework wherein macrostructural brain remodeling and molecular dysregulation interplay in complex, cell-type-specific manners. These insights illuminate novel targets for therapeutic intervention, potentially guiding precision medicine approaches addressing both neuroinflammatory and neurodevelopmental components of CSD.

The identification of cingulate and supramarginal morphometric aberrations underscores the importance of focusing future studies on neural circuitry involved in emotion, memory, and language—domains frequently impaired in COVID-19 survivors. Moreover, the coupling of MRI-derived network measures with transcriptomic data exemplifies a cutting-edge paradigm, highlighting the synergy achievable by integrating imaging genomics into psychiatric neuroscience.

Importantly, these findings hold profound implications beyond COVID-19, illustrating how viral infections can precipitate enduring changes in brain architecture mediated by gene expression shifts within specific neural cell populations. The potential parallels with other neuropsychiatric disorders characterized by neuroinflammation and developmental disruptions warrant expansive explorations.

In summary, this landmark investigation expands our neuroscientific lexicon by linking unique cortical morphometric inverse divergence alterations in treatment-naïve, first-episode CSD patients to distinct transcriptional signatures. It provides compelling evidence for neurodevelopmental and immune-related mechanisms driving secondary depression after COVID-19, advocating for multidimensional approaches to understanding and treating this emerging public health challenge. As the global community grapples with the lingering neuropsychiatric aftermath of the pandemic, such research paves the way toward deciphering the intricate biological tapestries woven by viral infection and brain function.

Subject of Research: The study investigates cortical morphometric inverse divergence alterations and their correlation with cortical transcriptional signatures in first-episode, treatment-naïve COVID-19 secondary depression patients.

Article Title: Cortical morphometric inverse divergence alterations in first-episode, treatment-naïve COVID-19 secondary depression correlate with transcriptional signatures

Article References:
Li, C., Lin, Q. & Yang, L. Cortical morphometric inverse divergence alterations in first-episode, treatment-naïve COVID-19 secondary depression correlate with transcriptional signatures. BMC Psychiatry 25, 1110 (2025). https://doi.org/10.1186/s12888-025-07544-2

Image Credits: AI Generated

DOI: 10.1186/s12888-025-07544-2 (Published 20 November 2025)

Keywords: COVID-19 secondary depression, cortical morphometry, inverse divergence, transcriptional signatures, neurodevelopmental pathways, immune response, MRI, partial least squares regression, neuroinflammation, cortical layers, gene expression, brain networks

The debilitating sequelae of COVID-19 have led to a complex syndrome—termed long COVID—characterized by persistent symptoms such as fatigue, dyspnea, cognitive impairment, and generalized malaise, long after the acute viral infection resolves. The pathophysiological mechanisms underlying long COVID remain incompletely understood but are hypothesized to involve persistent inflammation, dysregulated immune responses, endothelial damage, and microvascular dysfunction. Given colchicine’s established role in modulating inflammatory cascades, particularly through targeting microtubule polymerization and suppressing neutrophil activity, it emerged as a promising candidate for mitigating the chronic inflammatory states associated with this syndrome.

The clinical trial, spearheaded by a team led by Dr. Niveditha Devasenapathy, applied strict randomized methodologies to assess colchicine’s impact on key clinical parameters among adults with documented long COVID. The primary endpoints included functional capacity assessments—measuring patients’ ability to perform physical activities—respiratory function tests evaluating pulmonary performance, and quantification of systemic inflammatory biomarkers, which serve as proxies for ongoing immune activation. Comprehensive data analyses revealed that patients receiving colchicine exhibited no statistically significant improvement in these parameters compared to controls.

This lack of efficacy underscores the complexity and heterogeneity inherent in long COVID, suggesting that a singular anti-inflammatory strategy may be insufficient to address the multifaceted biological disruptions experienced by these patients. The trial highlights the urgent need for further mechanistic studies to unravel the molecular and immunological underpinnings of long COVID to enable development of rational therapeutics that target the condition’s diverse pathways more effectively.

Moreover, the negative findings from this robust clinical investigation hold important ramifications for future research directions and clinical practice. They caution against premature reliance on colchicine or similar agents without strong empirical support while emphasizing the necessity to explore alternative therapeutic modalities. Potential avenues warranting exploration include antiviral agents to address persistent viral reservoirs, immunomodulators tailored to specific inflammatory profiles, and interventions aimed at endothelial repair and mitochondrial function restoration.

Notably, this study contributes to a growing body of literature striving to delineate the natural history and treatment landscape of long COVID. Its rigorous randomized controlled design enhances the evidence base, providing clinicians and scientists with reliable data to inform patient management and guide resource allocation. As long COVID continues to affect millions worldwide, delineating effective treatments remains a public health imperative.

The trial also prompts reflection on the challenges of conducting large-scale clinical research amidst an evolving pandemic context, where heterogeneous patient populations, variable symptomatology, and fluctuating viral dynamics complicate study design and interpretation. Future investigations may benefit from stratifying patients based on immunological and clinical phenotypes, employing biomarker-driven approaches to customize therapeutic interventions.

Collaboration across disciplines—including immunology, pulmonology, infectious diseases, and rehabilitation medicine—is crucial to advancing understanding and care for long COVID. Integrating cutting-edge technologies such as multiomics, advanced imaging, and machine learning may expedite discovery of novel targets and predictive markers, ultimately facilitating precision medicine approaches.

As the global community grapples with the long-term consequences of SARS-CoV-2 infection, this study serves as a clarion call for sustained investment in research to unravel the enigmatic pathophysiology of long COVID. Only through rigorous scientific inquiry and innovation can effective treatments emerge to alleviate the suffering of millions enduring this chronic condition.

For individuals, health care professionals, and policymakers alike, these findings highlight the importance of managing expectations while encouraging participation in clinical trials to accelerate therapeutic breakthroughs. The journey to conquer long COVID is complex and ongoing, demanding resilience, collaboration, and scientific rigor.

In conclusion, while colchicine’s lack of benefit represents a setback, it simultaneously marks a step forward in refining our therapeutic strategies. The search for effective long COVID treatments continues, driven by the imperative to restore health and quality of life for survivors of this unprecedented pandemic challenge.

Subject of Research: Treatment efficacy in adults with long COVID

Article Title: Not specified in the provided content

News Publication Date: Not specified in the provided content

Web References: Not specified in the provided content

References: (doi:10.1001/jamainternmed.2025.5408)

Image Credits: Not applicable

Keywords: COVID 19, Medical treatments, Randomization, Clinical trials, Adults, Internal medicine

Despite the high prevalence and significant impact of Long COVID brain fog, the molecular underpinnings responsible for this cognitive dysfunction have remained elusive. Previous neuroimaging endeavors primarily revealed macroscopic structural alterations within the brain but failed to illuminate the specific neurochemical or receptor-level changes that directly contribute to cognitive deficits. This knowledge gap has hampered efforts to develop objective diagnostic biomarkers or targeted therapies that could alleviate brain fog symptoms. The complexity arises from the difficulty in directly visualizing key neurotransmitter receptors in the living human brain, a challenge that has limited direct assessment of synaptic molecular dysfunction in these patients.

Addressing these critical unknowns, a pioneering research group headed by Professor Takuya Takahashi at the Graduate School of Medicine, Yokohama City University, has made a landmark breakthrough in deciphering the molecular basis of Long COVID brain fog. Their research, recently published in the prestigious journal Brain Communications, leveraged cutting-edge positron emission tomography (PET) imaging with a novel tracer known as [^11C]K-2 to directly visualize and measure the density of AMPA-type glutamate receptors (AMPARs) in vivo. AMPARs play an essential role in fast excitatory neurotransmission and are fundamental to synaptic plasticity, learning, and memory—processes severely compromised in Long COVID patients.

By comparing PET scans from 30 subjects afflicted with Long COVID to 80 healthy controls, the investigators uncovered a striking and widespread increase in AMPAR density throughout multiple brain regions of affected individuals. Crucially, the degree of this receptor upregulation exhibited a robust correlation with the severity of cognitive impairment observed clinically. The data unmistakably establish a link between abnormal synaptic receptor expression and the cognitive symptoms characteristic of Long COVID brain fog, providing the first molecular biomarker connecting brain function alterations with clinical presentation.

Further examination revealed concomitant elevations in systemic inflammatory biomarkers tightly associated with AMPAR density increases, implicating a synergistic interaction between immune dysregulation and synaptic receptor remodeling. This connection offers a plausible mechanistic explanation for how persistent inflammation triggered by SARS-CoV-2 infection could drive maladaptive molecular changes within neural circuits, ultimately manifesting as cognitive dysfunction. These insights highlight the inflammatory milieu’s role in shaping neurotransmitter receptor populations and suggest inflammation-targeted interventions may complement receptor-focused therapies.

The implications of these findings are profound, as they redefine Long COVID brain fog as a biologically verifiable disorder with measurable molecular abnormalities rather than a nebulous symptom complex. The identification of AMPAR overexpression opens new avenues for therapeutic development, including the potential use of AMPAR antagonists—drugs capable of normalizing excessive receptor activity—to reverse or mitigate cognitive deficits. Moreover, the ability of PET imaging with [^11C]K-2 to distinguish Long COVID patients from healthy individuals with exceptional sensitivity (100%) and high specificity (91%) underscores its promise as a diagnostic tool for objectively confirming brain fog associated with Long COVID.

Professor Takahashi emphasizes the transformative nature of this approach, stating that applying advanced AMPAR PET imaging technology furnishes researchers and clinicians with a novel perspective and innovative solutions to the urgent medical challenge posed by Long COVID. While comprehensive treatments remain forthcoming, this study constitutes a pivotal step toward precision medicine strategies tailored to the molecular pathology of Long COVID brain fog.

Looking ahead, further research aimed at longitudinally monitoring AMPAR dynamics and inflammatory profiles in Long COVID patients may elucidate progression patterns and identify critical windows for therapeutic intervention. Integrating molecular imaging biomarkers with clinical phenotyping can refine patient stratification and accelerate the development of targeted pharmaceuticals aimed at synaptic receptor regulation and immune modulation.

The groundbreaking revelation that excessive AMPA receptor expression underpins cognitive impairment in Long COVID not only advances scientific understanding but also lends legitimacy and clarity to patients’ experiences. Recognizing Long COVID brain fog as an authentic neurological disorder with definable pathophysiology is crucial for galvanizing healthcare systems, regulatory agencies, and pharmaceutical companies to intensify efforts in diagnostic and treatment innovations.

This comprehensive study thus bridges a critical knowledge gap, shedding light on the complex neurobiological interplay between viral infection, immune response, and synaptic function disruption. The utilization of an innovative molecular brain imaging technique has unveiled concrete biological targets and offered a potential biomarker set that could revolutionize Long COVID research and clinical management worldwide.

In summary, the research led by Professor Takahashi and his colleagues constitutes a watershed moment in combating one of the most challenging facets of the COVID-19 pandemic’s legacy. By pinpointing a systemic increase in AMPA receptors tied to cognitive decline, this investigation lays the foundation for novel diagnostic tools and therapeutic strategies that could dramatically improve outcomes for millions suffering from Long COVID brain fog across the globe. Through continued multidisciplinary collaboration and technological innovation, hope is on the horizon to unravel and ultimately resolve this enigmatic post-viral syndrome.

Subject of Research: People

Article Title: Systemic increase of AMPA receptors associated with cognitive impairment of Long COVID

News Publication Date: 1-Oct-2025

Web References: https://doi.org/10.1093/braincomms/fcaf337

References: Takahashi, T., et al. (2025). Systemic increase of AMPA receptors associated with cognitive impairment of Long COVID. Brain Communications. DOI: 10.1093/braincomms/fcaf337

Image Credits: Professor Takuya Takahashi from Yokohama City University

Keywords: COVID 19, Neurology, Brain, Imaging, Cognitive neuroscience, Biomarkers, Diseases and disorders, Molecular biology, Public health, Medical treatments